Roopali Gandhi

Accomplished Global Medical Director at Sanofi with expertise in medical strategy development and KOL engagement. Proven track record in accelerating clinical programs and fostering cross-functional collaboration. Adept at biomarker research and mentoring future medical leaders, delivering impactful results in neurology and immunology.

MS Australian Research Society - Ad hoc Reviewer, NMSS - Ad hoc Reviewer, Clinical Immunology - Reviewer, Annals of Neurology - Reviewer, Neuromolecular Medicine - Reviewer, Neurological Research and Therapy - Editorial Board Member, Neuroimmunology and Neuroinflammation - Reviewer, Neurology and Neuroscience - Editorial Board Member, Multiple Sclerosis - Reviewer, American Academy of Neurology - Abstract Review Committee, NIH, Extracellular RNA consortium - Abstract Review Committee

• Biomarkers in Multiple Sclerosis, Paul A, Comabella M, Gandhi R., Cold Spring Harb Perspect Med., 03/01/19, 9, 3, a029058
• Alterations of the human gut microbiome in multiple sclerosis, Jangi S, Gandhi R, et al., Nat Commun., 06/28/16, 7, 12015, Equal first author
• Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells, Gandhi R, et al., Nature Immunology., 09/01/10, 11, 9, 846-53
• Cutting edge: human latency-associated peptide+ T cells: a novel regulatory T cell subset, Gandhi R, et al., Journal of Immunology, 05/01/10, 84, 9, 4620-4
• Circulating microRNAs as biomarkers for disease staging in multiple sclerosis, Gandhi R, et al., Annals of Neurology., 06/07/13, 73, 6, 729-40

• Harvard Catalyst Leadership Course, Harvard Medical School, Boston, MA, 2015
• Women's Leadership Program, Brigham and Women's Hospital, Boston, MA, 2015
• BWH Leadership Program, Brigham and Women's Hospital, Boston, MA, 2014
• Clinical Research Certificate, Boston College, Chestnut Hill, MA, 2008

Citizenship: US citizen